Oncology | Phase II Developments | SWEDEN

RhoVac AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany

Lead Product(s): RV001

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 23, 2020

Details:

First patient is being treated in BRaVac trial. This phase IIb-study clinical trial tests the effectiveness of RV001 in preventing the development after curative treatment of advanced prostate cancer.

Cantargia AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Cantargia Provides Update on Development Projects CAN04 and CAN10

Lead Product(s): Nidanilimab,Cisplatin,Gemcitabine

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 07, 2020

Details:

Dose level selected in CAN04 phase IIa for non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in the CANFOUR trial.

RhoVac AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Covid-19 Related Delays in RhoVac AB Ongoing Phase IIb-study are Expected to be Managed With Existing Funding

Lead Product(s): RV001

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 02, 2020

Details:

Company seeing signs of delays in the ongoing clinical phase IIb study with the drug candidate RV001 in prostate cancer, due to the Covid-19 pandemic.

Oncopeptides AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program

Lead Product(s): Melphalan Flufenamide,Dexamethasone

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2020

Details:

The company announced delay of a number of trials due to COVID-19 pandemic.

RhoVac AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

First patient in treatment for RhoVac's clinical phase II study in Finland

Lead Product(s): RV001V

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

The phase IIb study will recruit over 175 patients in six European countries and the US.

RhoVac AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial

Lead Product(s): RV001

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2020

Details:

BRaVac is aimed at evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative treatment.

Cantargia AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Cantargia Advances Development of CAN04 Through Successful Production Scale Up

Lead Product(s): Nidanilimab

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 14, 2020

Details:

The development of the CAN04 antibody is advancing and recently communicated data suggest a synergistic effect with chemotherapy.

Immunicum AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Immunicum AB Presents Updated Data from MERECA Trial of Ilixadencel

Lead Product(s): Ilixadencel

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 06, 2020

Details:

Survival as of December 2019 was 54% in the ilixadencel treatment group compared with 37% of patients in the control group treated with sunitinib monotherapy.

Immunicum AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Immunicum AB Announces Publication of Abstracts

Lead Product(s): Ilixadencel

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

Details:

The MERECA trial investigated Immunicum’s lead product, ilixadencel, in combination with Sutent® (sunitinib) as a first-line treatment in patients with metastatic kidney cancer.

RhoVac AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate Cancer

Lead Product(s): RV001

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

The phase IIb study is an international, multicenter study, which is expected to recruit more than 175 patients in EU, as well as in the United States.

Find

Find Oncology Drugs in Phase II Clinical Development in SWEDEN

Sweden

A collaboration with SCORR Marketing

Product Type

Companies

RhoVac AB

First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany

Cantargia AB

Cantargia Provides Update on Development Projects CAN04 and CAN10

RhoVac AB

Covid-19 Related Delays in RhoVac AB Ongoing Phase IIb-study are Expected to be Managed With Existing Funding

Oncopeptides AB

Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program

RhoVac AB

First patient in treatment for RhoVac's clinical phase II study in Finland

RhoVac AB

RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial

Cantargia AB

Cantargia Advances Development of CAN04 Through Successful Production Scale Up

Immunicum AB

Immunicum AB Presents Updated Data from MERECA Trial of Ilixadencel

Immunicum AB

Immunicum AB Announces Publication of Abstracts

RhoVac AB

RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate Cancer